Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by American Century Companies Inc.

American Century Companies Inc. lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 26.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 472,017 shares of the company's stock after selling 167,575 shares during the period. American Century Companies Inc. owned about 0.98% of Amphastar Pharmaceuticals worth $17,526,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of AMPH. Pacer Advisors Inc. grew its position in Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after buying an additional 1,347,775 shares during the period. Boston Trust Walden Corp grew its position in shares of Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after acquiring an additional 439,281 shares during the period. Boston Partners purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $15,778,000. Wealthfront Advisers LLC acquired a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $9,268,000. Finally, Hotchkis & Wiley Capital Management LLC purchased a new position in Amphastar Pharmaceuticals during the third quarter worth approximately $10,804,000. Hedge funds and other institutional investors own 65.09% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st.

Remove Ads

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. The trade was a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH traded down $0.63 during trading on Friday, hitting $26.61. The company had a trading volume of 699,408 shares, compared to its average volume of 445,475. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $25.89 and a fifty-two week high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a fifty day simple moving average of $30.24 and a two-hundred day simple moving average of $39.32. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 8.87, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.